10
Participants
Start Date
August 4, 2024
Primary Completion Date
September 20, 2024
Study Completion Date
May 28, 2025
Gemcitabine, Vinorelbine, or Eribulin
Gemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days
Sun Yat-sen University Cancer Center, Guangzhou
Sun Yat-sen University
OTHER